COMMUNIQUÉS West-GlobeNewswire

Anika Reports Fourth Quarter and Year-End 2023 Financial Results
13/03/2024
Revenue growth and adjusted EBITDA 1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives [...]
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
13/03/2024
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
Record full year 2023 net sales of $ 16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J., March 13, 2024 ( [...]
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
Maintained Strong Gross Profit Margin of 40.2% in Q4 2023 and 43.1% for FY 2023 Net Loss of $18.0 Million in Q4 2023 Compared to $139.9 Million in Q4 2022 Improved Adjusted EBITDA and Adjusted EBITDA Margin to $11.3 M [...]
PepGen to Participate in Upcoming Investor Conferences
13/03/2024
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of [...]
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13/03/2024
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints [...]
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
13/03/2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, [...]
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
13/03/2024
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Initiated enrollment in PIVOT-PO, a pivotal Phase 3 [...]
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
13/03/2024
Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® [...]
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
13/03/2024
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 million in [...]
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
13/03/2024
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief [...]
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
13/03/2024
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small [...]
Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2
13/03/2024
Daix (France), Long Island City (New York, États-Unis), le 13 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
13/03/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 13, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, [...]
Tilray Wellness Introduces New Superfood Products Powered by Hemp at Expo West
13/03/2024
Manitoba Harvest, Pioneers in Hemp and Natural Foods, Will Present New Superfood Breakfast Staples at Expo West March 13-15, 2024 NEW YORK and WINNIPEG, Manitoba, March 13, 2024 (GLOBE NEWSWIRE) -- Manitoba Harvest Hemp [...]
SAFE - Accélération des réorganisations pour un retour à une croissance durable et rentable
13/03/2024
Accélération des réorganisations pour un retour à une croissance durable et rentable Fleurieux-sur-l’Arbresle - France - le 13 mars 2024 à 18h . Fort de la mise en place d’un nouveau financement d’un montant minimum net [...]
Lifeward Announces Reverse Share Split
13/03/2024
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, [...]
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
13/03/2024
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy [...]

Pages